Trial
NCT00504101
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Miami
Collaborators
—
Condition
Multiple Myeloma and Plasma Cell Neoplasm
Intervention
Arsenic trioxide
Why stopped
Temporarily closed to accrual pending availablity of drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-15